Abbott Cuts $88.5M Deal To End Investors' Formula Recall Suit
Abbott Laboratories and a proposed class of shareholders have reached an $88.5 million settlement to resolve claims that the company misled investors about its safety practices ahead of the 2022 recall at...To view the full article, register now.
Already a subscriber? Click here to view full article